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In the present study we investigated the role of the fibronectin (FN)- and fibrinogen (FGN)-binding protein
(FBPS) in the pathogenesis of Streptococcus suis serotype 2 in piglets. The complete gene encoding FBPS from
S. suis serotype 2 was cloned in Escherichia coli and sequenced. The occurrence of the gene in various serotypes
was analyzed by hybridization studies. The FBPS protein was expressed in E. coli and purified, and binding to
human FN and FGN was demonstrated. The induction of antibodies in piglets was studied upon infection. An
isogenic mutant unable to produce FBPS was constructed, and the levels of virulence of the wild-type and
mutant strains were compared in a competitive infection model in young piglets. Organ cultures showed that
FBPS was not required for colonization of the tonsils but that FBPS played a role in the colonization of the
specific organs involved in an S. suis infection. Therefore, the FBPS mutant was considered as an attenuated
mutant.
Streptococcus suis causes severe infections in piglets. The
bacterial infections include meningitis, septicemia, and arthri-
tis, and the animals often do not survive the infection (6, 28).
Occasionally, S. suis causes septicemia and meningitis in hu-
mans (3). The pathogenesis of an S. suis infection is rarely
understood. Sows are symptomless carriers of S. suis on their
tonsils and pass the bacteria on to their piglets. The piglets
cannot cope with the bacterium and subsequently develop the
specific symptoms of an S. suis infection. Until now, 35 capsu-
lar serotypes of S. suis have been described (26), but serotype
2 strains are most often isolated from diseased piglets. Capsule
is an important virulence factor, since piglets infected with an
acapsular mutant of S. suis serotype 2 strains do not develop
any clinical symptoms (22). Bacterial proteins have been sug-
gested to play a role in the pathogenesis as well (1, 26). The
expression of muramidase-released protein (MRP), extracel-
lular factor (EF), and suilysin was shown to be strongly asso-
ciated with pathogenic strains of S. suis serotype 2 (2, 29, 30).
Since isogenic mutants lacking MRP and EF and isogenic
mutants lacking suilysin were still pathogenic for young piglets,
these proteins are not absolutely required for virulence (1, 23).
Recently, a new virulence factor was identified (21) by using a
complementation approach. The function of this virulence fac-
tor in the pathogenesis has to be further investigated.
Many important virulence factors are environmentally reg-
ulated and are induced at specific stages of the infection pro-
cess (15). To identify these genes in S. suis, we cloned promot-
ers and their downstream sequences that are “on” during
experimental S. suis infection of piglets (20). Twenty-two in
vivo-selected (ivs) genes were found. Two of the ivs genes were
directly linked to virulence, since homology to genes in the
database that encode for known virulence factors was found.
One of these ivs genes (ivs-21) was identical to the epf gene of
virulent S. suis serotype 2 strains (30). The other (ivs-31)
showed homology to genes encoding fibronectin (FN)- and/or
fibrinogen (FGN)-binding proteins of Streptococcus gordonii
(GenBank accession no. X65164) and Streptococcus pyogenes
FBP54 (8). A considerable number of FN-binding proteins of
various bacterial species have been shown to be important
virulence factors (12). In S. pyogenes, FBP54 was shown to be
expressed in the human host and to preferentially mediate
adherence to human buccal epithelial cells (7). It was recently
shown that the FBP54 protein induces protective immunity
against S. pyogenes challenge in mice (13).
In the present study we describe an FN- and FGN-binding
protein of S. suis (FBPS). The sequence of fbps was deter-
mined. Binding studies showed that purified FBPS bound FN
and FGN. A contribution of FBPS to the pathogenesis of S.
suis serotype 2 was found.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains and plasmids
used in this study are listed in Table 1. S. suis strains were grown in Todd-Hewitt
broth (code CM 189; Oxoid, Ltd., London, United Kingdom) and plated on
Columbia blood base agar plates (code CM 331; Oxoid, Ltd.), containing 6%
(vol/vol) horse blood. Escherichia coli strains were grown in Luria broth (17) and
plated on Luria broth containing 1.5% (wt/vol) agar. If required, the following
antibiotics were added at the indicated concentrations: spectinomycin (Sigma, St.
Louis, Mo.) (50 g/ml for E. coli and 100 g/ml for S. suis), ampicillin (Boehr-
inger, Mannheim, Germany) (100 g/ml for E. coli), and kanamycin (Boehr-
inger) (25 g/ml for E. coli).
DNA techniques and sequence analysis. Routine DNA manipulations were
performed as described by Sambrook et al. (19). DNA sequences were deter-
mined on a 373A DNA Sequencing System (Applied Biosystems, Warrington,
Great Britain). Samples were prepared by use of an ABI Prism dye terminator
cycle sequencing ready reaction kit (Applied Biosystems). Sequencing data were
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assembled and analyzed using the Lasergene program (DNASTAR). The
BLAST software package was used to search for protein sequences homologous
to the deduced amino acid sequences in the GenBank and EMBL databases.
Southern blotting and hybridization. Chromosomal DNA was isolated as
described by Sambrook et al. (19). DNA fragments were separated on 0.8%
agarose gels and transferred to GeneScreen Plus hybridization transfer mem-
brane (NEN Life Science Products, Boston, Mass.) as described by Sambrook et
al. (19). DNA probes of the fbps and spc genes were labeled with [-32P]dCTP
(3,000 Ci/mmol; Amersham Life Science, Little Chalfont, Buckinghamshire,
Great Britain) by use of a random primed DNA labeling kit (Boehringer). The
DNA on the blots was prehybridized for at least 30 min at 65°C and subsequently
hybridized for 16 h at 65°C with the appropriate DNA probes in a buffer
containing 0.5 M sodium phosphate (pH 7.2), 1 mM EDTA, and 7% sodium
dodecyl sulfate (SDS). After hybridization, the membranes were washed twice
with a buffer containing 40 mM sodium phosphate (pH 7.2), 1 mM EDTA, and
5% SDS for 30 min at 65°C and twice with a buffer containing 40 mM sodium
phosphate (pH 7.2), 1 mM EDTA, and 1% SDS for 30 min at 65°C. The signal
was detected on a phosphorimager (Storm; Molecular Dynamics, Sunnyvale,
Calif.).
Construction of an fbps knockout mutant. To construct the mutant strain 10
FBPS, the pathogenic strain 10 (27, 29) of S. suis serotype 2 was electrotrans-
formed (24) with the plasmid pFBPS7-47. In this plasmid, the fbps gene was
inactivated by the insertion of a spectinomycin resistance gene. To create
pFBPS7-47 (Fig. 1) the 382-bp SalI-SalI fragment of pFBPS7-46 was replaced by
the 1.2-kb EcoRV-SmaI fragment of pIC-Spc, containing the spectinomycin
resistance gene, after the SalI sites of the vector were made blunt (Fig. 1). After
electrotransformation of strain 10 with pFBPS7-47, spectinomycin-resistant col-
onies were selected on Columbia agar plates containing spectinomycin (100
g/ml). Southern blotting and hybridization experiments were used to select for
double-crossover integration events (data not shown).
FBPS expression construct. To construct an FBPS expression plasmid the
QIA expressionist kit (Qiagen GmbH, Hilden, Germany) was used. The primers
corresponded to positions 250 to 272 and positions 1911 to 1892 of the fbps gene.
The sequences of these primers were 5-GCGGATCCGATGACGATGACAA
ATCTTTTGACGGATTTTTTTTAC-3 and 5-CCCAAGCTTGGGCATGAA
CTAGATTTTCATGG-3. The primers contained restriction sites for BamHI
and HindIII, respectively, to amplify the fbps gene from pFBPS7-47. The ampli-
fied PCR product was digested with BamHI and HindIII, and the 1.8-kb fbps
gene was cloned into pQE-30 digested with BamHI and HindIII, yielding pQE-
30-FBPS. pQE-30-FBPS was transformed to M15[pREP4].
Purification of FBPS. M15[pREP4][pQE-30-FBPS] was used to express and to
purify the FBPS using the QIA expressionist (Qiagen). In short, M15[pREP4]
[pQE-30-FBPS] cells were grown exponentially; 1 mM IPTG was added, and the
cells were allowed to grow another 4 h at 37°C. Subsequently, cells were har-
vested and lysed. The cleared supernatants were loaded onto Ni2-nitrilotriace-
tic acid agarose columns. FBPS containing a six-His tag was bound to the Ni2
column. The columns were washed and the protein was eluted. Different buffers
were used for native and for denaturing purification. FBPS purified under de-
naturing conditions was renatured on an Ni2-nitrilotriacetic acid column by
using a linear urea gradient (6 M to 1 M) in 500 mM NaCl, 20% glycerol, and 20
mM Tris-HCl (pH 7.4), containing protease inhibitors (per milliliter: 25 g of
Pefabloc, 0.7 g of pepstatin, 1 g of aprotinin, and 0.5 g of leupeptin). All
procedures were performed according to the manufacturer’s recommendations.
The six-His tag was removed from the protein by incubating purified FBPS in a
solution containing 20 mM Tris-HCl (pH 7.4), 50 mM NaCl, 2 mM CaCl2, and
FIG. 1. Schematic presentation of the procedure used to clone the
fbps gene of S. suis serotype 2 and the construction of an insertional
knockout mutant in S. suis serotype 2. A 5-kb EcoRI fragment was
cloned in pGEM7Zf(), yielding pFBPS7-46. In pFBPS7-47, the
382-bp SalI-SalI fragment of pFBPS7-46 was replaced by a 1.2-kb
spectinomycin resistance gene, after the vector was made blunt, to
obtain an insertional knockout of fbps.
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s)a Source or reference
Strains
E. coli
XL2-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F proAB lacIqZM15 Tn10(Tetr)
amy Cmr]
Stratagene
M15 Nals Strs Rifs Thi Lac Ara Gal Mtl F RecA Uvr Lon Qiagen
S. suis
10 Virulent serotype 2 strain 29
10FBPS Isogenic fbps mutant of strain 10 This work
Plasmids
pGEM7Zf() Replication functions pUC, Ampr Promega Corp.
pKUN19 Replication functions pUC, Ampr 14
pIC19R Replication functions pUC, Ampr 16
pDL282 Replication functions of pBR322 and pVT736-1, Ampr Spcr 25
pIC-spc pIC19R containing Spcr gene of pDL282 Laboratory collection
pQE-30 Replication functions pBR322, Ampr, expression vector, six-His tag Qiagen
pQE-30-FBPS pQE-30 containing the 1.8-kb fbps gene This work
pREP4 Replication functions pACYC, Kanr, lacI gene Qiagen
pE194 Emr 11
pIVS-E Replication functions of pWV01, Spcr, promoterless erm gene of pE194 20
pIVS-31 pIVS-E containing 200 bp showing homology to Streptococcus gordonii flpa 20
pFBPS7-46 pGEM7Zf() containing EcoRI-EcoRI fragment of fbps This work
pFBPS7-47 pFBPS7-46 in which 382-bp SalI-SalI fragment is replaced by 1.2-kb Spcr from pIC-spc This work
a Tetr, tetracycline resistant; Cmr, chloramphenicol resistant; Ampr, ampicillin resistant; Spcr, spectinomycin resistant; Kanr, kanamycin resistant.
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0.5 U of light-chain enterokinase (New England Biolabs, Beverly, Mass.) for 16 h
at room temperature (RT).
Immunization of rabbits with FBPS. Purified and renatured FBPS was used to
immunize two rabbits. To remove urea the protein was dialyzed against phos-
phate-buffered saline (136 mM NaCl, 2.68 mM KCl, 8.1 mM Na2HPO4, 2.79 mM
KH2PO4 [pH 7.2]) (PBS) overnight at 4°C. Seven days before immunization,
blood was collected from the rabbits to determine the natural titers of antibody
against FBPS. At day 1 those rabbits with negative anti-FBPS titers were immu-
nized intramuscularly with two injections of 0.5 ml of 100-g/ml FBPS in a
water-in-oil emulsion (Specol; ID-Lelystad, Lelystad, The Netherlands). At day
28, rabbits were immunized for the second time using the same amount of
protein and the same route of immunization. Three weeks after the second
immunization the rabbits were sacrificed and blood was collected. The blood was
coagulated and serum was collected and used for immunodetection of FBPS.
Immunodetection of FBPS. Proteins were separated by SDS-polyacrylamide
gel electrophoresis (PAGE) by standard procedures (19). Proteins in the gel
were visualized using SYPRO-orange (Molecular Probes, Sunnyvale, Calif.)
staining according to the manufacturer’s recommendations. Signals were de-
tected on a phosphorimager (Storm; Molecular Dynamics). A known bovine
serum albumin concentration range was used as a standard to calculate the
amounts of protein present in the gel. The Molecular Dynamics program was
used for the calculations.
Proteins were transferred to a nitrocellulose membrane by standard proce-
dures (19). The membranes were blocked in Blotto–Tris-buffered saline (50 mM
Tris-HCl [pH 7.5], 150 mM NaCl) (Blotto-TBS) containing 4% skim milk and
0.05% Tween 20, at RT for 1 h. To detect recombinant purified FBPS, mem-
branes were incubated with a monoclonal antibody against the six-His tag (Clon-
tech, Palo Alto, Calif.) in a 1:10,000 dilution in Blotto-TBS (1:1) at RT for 1 h,
followed by an incubation with alkaline phosphatase-conjugated anti-mouse an-
tibody in a 1:1,000 dilution in Blotto-TBS (1:1) at RT for 1 h. Reactivity of
purified FBPS was tested by using a convalescent-phase serum of a pig that had
survived an S. suis infection. Nitrocellulose membranes were incubated with the
polyclonal pig serum in a 1:200 dilution in Blotto-TBS (1:1) at RT for 1 h,
followed by an incubation at RT for 1 h with alkaline phosphatase-conjugated
anti-swine antibody in a 1:2,000 dilution in Blotto-TBS (1:1). As a substrate Nitro
Blue Tetrazolium (Merck, Darmstadt, Germany)-bromochloroindolyl phosphate
(Sigma) was used. All washing steps were performed in Blotto-TBS (1:1).
FN and FGN binding. Binding studies were performed by indirect Western
blotting. Proteins were separated by SDS-PAGE and transferred to a nitrocel-
lulose membrane as described above. The membranes were blocked in MPBS
(PBS containing 4% skim milk and 0.05% Tween 20). Subsequently, the mem-
brane was incubated with human FN (5 g/ml; Sigma) or human FGN (5 g/ml;
Sigma) in PBS containing 5% fetal calf serum, 2% NaCl, and 0.05% Tween 80
at RT for 1 h. To detect bound FN and FGN, the membranes were incubated
with horseradish peroxidase-conjugated anti-FN (DAKO) or anti-FGN (DAKO)
antibodies in a 1:1,000 dilution in PBS containing 5% fetal calf serum, 2% NaCl,
and 0.05% Tween 80 at RT for 1 h. The signal was visualized by using an ECL
kit (Amersham Life Science) according to the manufacturer’s recommendations.
Signals were detected on a phosphorimager (Storm; Molecular Dynamics). All
washing steps were performed in MPBS-PBS (1:1).
Experimental infections. Germfree piglets, crossbreeds of Great Yorkshire
and Dutch Landrace, were obtained from sows by cesarean sections. The surgery
was performed in sterile flexible film isolators. Piglets were allotted to groups of
4, and were housed in sterile stainless steel incubators. Housing conditions and
feeding regimens were as described before (27, 29). Six-day-old piglets were
inoculated intranasally with about 107 CFU of Bordetella bronchiseptica 92932, to
predispose the piglets to infection with S. suis. Two days later they were inocu-
lated intranasally with 106 CFU of S. suis strain 10 plus 106 CFU of S. suis strain
10 FBPS. To determine differences in virulence between wild-type and mutant
strains, 50% lethal doses should be determined. To do this, large numbers of
piglets would be required. For ethical reasons this is not acceptable. To circum-
vent this problem we decided to perform cocolonization studies. To monitor for
the presence of S. suis and B. bronchiseptica and to check for absence of con-
taminants, swabs taken from the nasopharynx and the feces were cultured three
times a week. The swabs were plated directly onto Columbia agar containing 6%
horse blood or grown for 48 h in Todd-Hewitt broth and subsequently plated
onto Columbia agar containing 6% horse blood. Pigs were monitored twice a day
for clinical signs and symptoms, such as fever, nervous signs, and lameness. Blood
samples from each pig were collected three times a week. Leukocytes were
counted with a cell counter. The piglets were killed when specific signs of an S.
suis infection were observed, such as arthritis or meningitis, or when the pigs
became mortally ill. The other piglets were killed 2 weeks after inoculation with
S. suis and examined in the same way as the piglets that were killed based on their
clinical symptoms. All piglets were examined for pathological changes. Tissue
specimens from heart, lung, liver, kidney, spleen, and tonsil and from the organs
specifically involved in an S. suis infection (central nervous system [CNS], sero-
sas, and joints) were sliced with a scalpel or a tissuemizer. Tissue slices from each
organ or site were resuspended in 2 to 25 ml of Todd-Hewitt broth containing
15% glycerol, depending on the size of the tissue slice. The suspension was
centrifuged at 1,200  g for 5 min. The supernatant was collected and serial
dilutions were plated on Columbia agar containing 6% horse blood, as well as on
Columbia agar plates containing 6% horse blood and 100 g of spectinomycin
per ml to quantitate the number of wild-type and mutant bacteria present. The
number of mutant strain 10 FBPS cells was determined by counting the number
of CFU on the appropriate serial dilution on the selective plates; the number of
wild-type strain 10 cells was determined by counting the number of CFU on the
appropriate serial dilution on the Columbia agar blood plates, from which the
number of CFU counted on the selective plates was subtracted. When wild-type
and mutant bacteria were found in tissues, the ratio of wild-type and mutant
strain was determined again, by moving about 100 individual colonies by tooth-
pick onto both Columbia agar plates and onto Columbia agar plates containing
spectinomycin (100 g/ml).
All animal experiments were approved by the ethical committee of the Insti-
tute for Animal Science and Health, Lelystad, The Netherlands, in accordance
with the Dutch law on animal experiments.
Nucleotide sequence accession number. The nucleotide sequence data of fbps
have been submitted to GenBank under accession no. AF438158.
RESULTS
Cloning of the S. suis fbps gene. One of the in vivo-selected
genes (ivs-31) (20) showed homology to the 5 part of genes
coding for FlpA and FBP54, FN binding proteins (FnBP) of S.
gordonii (GenBank accession no. X65164) and S. pyogenes (8),
respectively. To clone the entire fbps gene of S. suis, ivs-31 was
subsequently used as a probe to identify a chromosomal DNA
fragment of S. suis serotype 2 containing flanking fbps se-
quences. A 5-kb EcoRI fragment was identified and cloned in
pGEM7Zf() yielding pFBPS7-46 (Fig. 1). Sequence analysis
revealed that this fragment contained the entire fbps gene of S.
suis serotype 2. An open reading frame of 1,659 bp coding for
a polypeptide of 553 amino acids was found. The putative ATG
start codon is preceded by a sequence similar to ribosome
binding sites of gram-positive bacteria. Further upstream, two
putative promoter sequences could be identified. Upstream of
these promoter sequences of fbps an inverted repeat was found
that could serve as a transcription terminator of the gene
located 5 of fbps. Downstream of fbps a gene was found that
showed homology to an alpha-acetolactate decarboxylase was
found. This gene is transcribed in the opposite direction of
fbps. The deduced amino acid sequence was aligned with that
of several previously identified FnBPs from other bacteria. As
expected, FBPS was very homologous to FlpA of S. gordonii
(76%) and also showed homology to FnBPs of other organ-
isms, like Streptococcus pneumoniae (73%), S. pyogenes (69%),
Lactococcus lactis (59%), and Bacillus subtilis (41%). Com-
pared to the sequence of FBP54, FBPS has a longer N termi-
nus with 76 additional amino acids. This longer N terminus was
also seen in other organisms like S. gordonii, S. pneumoniae,
and B. subtilis. In FBP54 the primary FN-/FGN-binding do-
main was localized to its N-terminal part, to the first 89 amino
acids (8). Over this region the homology of FBPS to FBP54 is
very high (80%) suggesting that FBPS can bind both FN and
FGN.
Binding of FBPS to FN and FGN. To confirm the binding of
FBPS of S. suis to FN and FGN, FBPS was purified under
native conditions. A protein expression construct, which ex-
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presses FBPS with a six-His tag fused to the N terminus, was
used for this purification. Four hundred g of FBPS was pu-
rified from 50 ml of exponential-phase E. coli cells after induc-
tion with IPTG. The purity of this FPBS was determined with
SDS-PAGE and Western blotting (Fig. 2). The induced E. coli
lysate contained a broad range of proteins, among which the
64-kDa protein FBPS was very clearly present (Fig. 2A, lane
1). After purification, highly purified FBPS with six-His tag was
obtained (Fig. 2A, lane 2). When both samples were incubated
with a monoclonal antibody against the six-His tag, FBPS was
the only protein that was detected (Fig. 2B).
To determine whether FBPS binds FN and FGN, a Western
blot containing purified FBPS was incubated with soluble hu-
man FN and human FGN (Fig. 3A and B). Specific binding of
FN and FGN to FBPS was clearly detected. No binding of FN
and FGN to BSA, a negative control protein, was observed. To
exclude possible background signals due to immunoglobulin-
binding of FBPS, the same experiment was performed without
addition of FN or FGN. No binding was found (Fig. 3C and D),
indicating that the binding was specific for FN and FGN. To
control whether the binding of FN and FGN to FBPS, was not
mediated by the six-His tag, the tag was removed by an en-
terokinase treatment. Figure 3E and F clearly show that FBPS
without the six-His tag, still efficiently bound to FN and FGN.
Therefore, it was concluded that FBPS can specifically bind to
FN and FGN.
Immunogenicity of FBPS. Since it was shown that FBP54
induced a protective immune response in mice against a lethal
dose of S. pyogenes (13), we next determined whether purified
FBPS was recognized by convalescent-phase serum of a pig
that survived an S. suis infection. As shown in Fig. 2 panel C,
the FBPS clearly reacted with this antiserum. When the same
experiment was performed with nonimmune serum of an SPF
piglet, no band of the size of FBPS was detected (data not
shown). These findings indicate that FBPS is expressed in vivo
and that the protein is indeed immunogenic in young pigs.
Distribution of the fbps gene among the 35 S. suis serotypes.
Since we were interested in a cross-protective vaccine candi-
date, we next analyzed the presence of the fbps gene among the
various S. suis serotypes. ivs-31, the clone containing the pro-
moter and the 5 part of the fbps gene was radiolabeled, and
chromosomal DNA of the reference strains of the 35 different
S. suis serotypes was hybridized with this probe. The three
different phenotypes of S. suis serotype 2—a pathogenic, a
FIG. 2. Purity and immunogenicity of FBPS purified under native
conditions. SDS-PAGE analysis with SYPRO-orange, a nonspecific
protein-staining dye (A), and Western blot analysis with a monoclonal
antibody against the six-His tag (B) of 4 l of E. coli M15 [pQE-30-
pREP4-FBPS] lysate (lanes 1) and 165 ng of purified FBPS (lanes 2)
were carried out. Convalescent-phase serum raised against S. suis
strain 10 was used to test immunogenicity of FPBS present in 4 l of
E. coli M15 [pQE-30-pREP4-FBPS] lysate and 0.5 g of purified FBPS
(C) (lanes 1 and 2). Arrowhead, 64-kDa FPBS; Mw, molecular size
marker (in kilodaltons).
FIG. 3. Binding studies with purified FBPS. (A and B) Gels were probed with FN (A) or FGN (B) at 5 g/ml. Lanes 1 contain 500 ng of purified
FBPS, and lanes 2 contain 500 ng of BSA. (C and D) Lanes 3 and 4 contain 500 ng of purified FBPS. Lanes 3 were probed with FN (C) or FGN
(D) at 20 g/ml, and lanes 4 were only incubated with conjugate without FN or FGN. (E and F) Gels were probed with FN (E) or FGN (F) at
20 g/ml. Lanes 5 contain 1.8 g of purified FBPS digested with enterokinase, and lanes 6 contain 500 ng of purified FBPS. The closed arrowhead
indicates 64-kDa FBPS; the open arrowhead indicates approximately 55-kDa FBPS without the six-His tag. Mw, molecular size marker (in
kilodaltons).
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nonpathogenic, and a weakly pathogenic strain—were in-
cluded in this study as well. The fbps gene was present in all S.
suis serotypes and phenotypes, except for serotypes 32 and 34
(Fig. 4).
Role of FBPS in pathogenesis. To test the role of FBPS in
the pathogenesis of S. suis, an isogenic knockout mutant of
FBPS was constructed in strain 10, strain 10FBPS. Since
upstream of fbps an inverted repeat was found that could serve
as a transcription terminator and downstream of fbps a gene
showing homology to an alpha-acetolactate decarboxylase was
found that is transcribed in the opposite direction, polar effects
on genes upstream or downstream of fbps are not expected. To
verify that the mutant strain 10FBPS did not produce FBPS,
protoplasts of strain 10 and strain 10FBPS were subjected to
SDS-PAGE and Western blotting. FBPS was detected using a
polyclonal antiserum raised against purified FBPS. It was
shown that strain 10 41 FBPS expressed no FBPS, while strain
10 did (data not shown). Subsequently the virulence of this
mutant strain was tested in an experimental infection in piglets.
The mutant strain 10FBPS was used in a competition chal-
lenge experiment with the wild-type strain to determine the
relative attenuation of the mutant strain. Under in vitro con-
ditions, the growth rates of the wild-type and mutant strain in
Todd-Hewitt medium were found to be essentially identical
(data not shown). Wild-type and mutant strains were inocu-
lated at an actual ratio of 0.65 (1.63  1066 CFU of wild-type
bacteria ml1 and 3.09  106 CFU of mutant bacteria ml1).
During the experiment, piglets that developed specific S. suis
symptoms (meningitis, arthritis, or mortal illness) were killed.
Piglets that did not develop these symptoms were killed at the
end of the experiment. From all piglets the ratio of wild-type
strain to mutant strain in various organs was determined. As
shown in Fig. 5A, similar numbers of wild-type and mutant
bacteria were reisolated from tonsils. The ratio was similar to
the input ratio (ratio varied from 0.33 to 0.85; average, 0.61).
This clearly indicates that the efficiencies of colonization of
wild-type and mutant strains on tonsils were essentially iden-
tical. Apparently, FBPS is not strictly required for colonization
of the tonsils of the piglets. Three out of four piglets developed
clinical signs specific for an S. suis infection. Two piglets (4664
and 4666) showed clinical signs of arthritis, and one piglet
(4668) showed clear central nervous signs. The fourth piglet
did not develop any clinical signs. These observations coin-
cided with pathomorphological abnormalities of the specific
organs of an S. suis infection in postmortem sections. As shown
in Fig. 5B and Table 2, exclusively wild-type bacteria were
reisolated from the joints of piglet 4664 and from the CNS of
piglet 4668. The numbers of CFU of wild-type bacteria that
were reisolated from these specific organs were very high,
while absolutely no mutant bacteria were found. From the
joints of pig 4666 low numbers of both wild-type and mutant
bacteria were reisolated in a ratio of 0.84 (1.0  102 CFU of
wild-type bacteria and 5.2  102 CFU of mutant bacteria), a
ratio essentially identical to the input ratio (Fig. 5B and Table
2). Southern blot experiments, using the fbps and the spc genes
as probes, confirmed that the mutant bacteria isolated from the
joint of pig 4666 were indeed identical to the input mutant
bacteria. Taken together, these data indicate that the FBPS
mutant is capable of reaching and colonizing the specific S. suis
organs (at least the joints) but that the mutant is far less
efficiently recovered from organs than the wild type.
DISCUSSION
In this work we describe the first FBPS of S. suis. The gene
encoding FBPS was cloned and sequenced, and FBPS was
FIG. 4. Distribution of fbps among various S. suis serotypes. Chro-
mosomal DNA (1 g) was spotted onto nitrocellulose membrane and
hybridized with a 32P-labeled fbps probe. Serotypes were spotted as
indicated. S10, S. suis serotype 2 MRP EF; T15, S. suis serotype 2
MRP EF; S17, S. suis serotype 2 MRP EF* (23).
FIG. 5. Efficiency of colonization of wild-type and mutant bacteria on various organs of infected pigs. (A) Colonization of the wild-type strain
10 (wt) and the mutant strain 10FBPS of the tonsils. Symbols: }, tonsil from pig 4664; , tonsil from pig 4665; Œ, tonsil from pig 4666; F, tonsil
from pig 4668. (B) Colonization of the specific organs. Symbols: { and }, pus from joints from pig 4664; Œ, pus from a joint from pig 4666; F,
CNS specimen from pig 4668. Each symbol represents the numbers of wild-type or mutant bacteria isolated from one particular organ, from one
piglet.
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purified. Binding of FBPS to human FN and FGN was shown.
FBPS was shown to be involved in the colonization of the
organs specific for an S. suis infection in piglets, but not in the
colonization of S. suis on the tonsils of piglets.
Many streptococci and staphylococci have several different
FnBPs, most of which are very large, about 130 kDa (12). Until
now, S. pyogenes is the only organism having a large as well as
a smaller (54-kDa) FnBP (8). The existence of more than one
FnBP explains why in some organisms isogenic mutants defec-
tive in only one of the FnBPs can still bind to FN and/or FGN
and are not completely attenuated in vivo (10). Although, so
far no FnBP other than that described here has been described
for S. suis, their existence could explain the fact that the FBPS
mutant is not completely attenuated in vivo.
A considerable number of FN- and FGN-binding proteins of
various bacterial species have been described (12). Most of
these proteins were shown to be involved in adhesion to epi-
thelial and/or endothelial cells (5, 8, 18). Therefore, it is at-
tractive to assume a similar role for FBPS of S. suis. Previously,
Charland and coworkers used human brain microvascular en-
dothelial cells (HBMEC) in an in vitro blood-brain barrier
model to study the pathogenesis of S. suis meningitis. Since S.
suis adhered to HBMEC (4) in future experiments it would be
of interest to test whether FBPS is involved in binding to
HBMEC and involved in crossing the blood-brain barrier.
The role of FBPS in the pathogenesis of S. suis was studied
in an experimental infection model in piglets. Since we were
unable to determine a 50% lethal dose for the mutant strains,
it was decided to compare the virulence of the isogenic FBPS
mutant to that of the wild-type S. suis strain in a competitive
infection assay in piglets. This kind of cocolonization experi-
ment has been successfully applied to determine the virulence
of mutants of Actinobacillus pleuropneumoniae in piglets (9).
The data clearly showed that the mutant strain was capable of
colonizing the tonsil as efficiently as the wild-type strain. This
strongly indicates that FBPS is not involved in the colonization
of the tonsil. The data also indicated that FBPS does play a
role in the colonization of specific organs, since in the compe-
tition assay joints and the CNS were more efficiently colonized
by wild-type than by mutant bacteria. In addition, higher num-
bers of wild-type bacteria were reisolated from the specific
organs compared to the numbers of mutant bacteria, indicating
that the mutant strain is attenuated in vivo. Although the
number of pigs used for this experiment was low, these data
indicate that the FBPS mutant is less virulent than the wild-
type strain. Loss of virulence of S. suis was also described by
Allen et al. (1). They constructed an isogenic knockout mutant
of suilysin in a pathogenic serotype 2 strain of S. suis, and
tested this mutant in an experimental animal model in pigs.
From their findings, it was concluded that suilysin might play a
role in reaching higher levels of colonization of various organs
after S. suis has gained entrance into the bloodstream.
We were able to demonstrate that FBPS reacted with a
convalescent-phase serum of a pig that survived an S. suis
infection. Therefore FBPS is immunogenic in pigs, and this
finding clearly demonstrates that FBPS of S. suis is expressed
under in vivo conditions. Recently, it was reported that FBP54
of S. pyogenes is expressed in the human host (7). The in vivo
expression of FBPS confirms the selection of the fbps gene
from a gene library under in vivo conditions, as described by
Smith and coworkers (20).
We showed that the fbps gene was present in all known
serotypes of S. suis (except for two), as well as in all three
phenotypes of serotype 2. This suggests that the fbps gene is
present among most serotypes. However, the expression of
FBPS in all serotypes and phenotypes was not studied. There-
fore, it is possible that although all strains, except for serotypes
32 and 34, possess the fbps gene, not all strains express FBPS.
Based on the facts that FBPS is immunogenic in pigs and that
the fbps gene is present in all prevailing S. suis serotypes except
for serotypes 32 and 34, FBPS is a very attractive candidate for
a cross-protective vaccine against all serotypes. Since the mu-
tant strain 10  FBPS is not completely attenuated, this vaccine
should be based on purified protein with a suitable adjuvant.
This idea is supported by recent data from Kawabata et al. (13)
which showed that vaccination with purified FBP54 can protect
mice against a S. pyogenes infection.
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